Karina Kalasuba

Ms. Karina Kalasuba

Department of Biology, Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Plants
Verified
Journal Article
Open access
PDF file
Karina KalasubaKarina Kalasuba
Karina Kalasuba
Mia MirantiMia Miranti
Mia Miranti
SRSri Rejeki Rahayuningsih
Sri Rejeki Rahayuningsih
WSWahyu Safriansyah
Wahyu Safriansyah
RSRizky Riscahya Pratama Syamsuri
Rizky Riscahya Pratama Syamsuri
Febri DoniFebri Doni
Febri Doni
Mangroves are ecologically significant plants in marine habitats that inhabit the coastlines of many countries. Being a highly productive and diverse ecosystem, mangroves are rich in numerous classes of phytochemicals that are of great importance in the field of pharmaceutical industries. The red mangrove (Rhizophora stylosa Griff.) is a common member of the Rhizophoraceae family and the dominant species in the mangrove ecosystem of Indonesia. R. stylosa mangrove species are rich in alkaloids, flavonoids, phenolic acids, tannins, terpenoids, saponins, and steroids, and are widely used in traditional medicine for anti-inflammatory, antibacterial, antioxidant, and antipyretic effects. This review aims to provide a comprehensive understanding of the botanical description, phytochemical profiles, pharmacological activities, and medicinal potentials of R. stylosa.

23 May 2025 in Orthopedic Reviews
Verified
Journal Article
Open access
PDF file
KDKeri Lestari Dandan
Keri Lestari Dandan
TPTerawan Agus Putranto
Terawan Agus Putranto
CSCynthia Retna Sartika
Cynthia Retna Sartika
AWAndi Wijaya
Andi Wijaya
DMDicky Mulyadi
Dicky Mulyadi
BPBilly Yoshua Constantin Pongajow
Billy Yoshua Constantin Pongajow
Osteoarthritis (OA) is a progressive and chronic disease that can result in the patient’s increased pain and loss of function. There might be some potential approaches to improve the recovery with mesenchymal stem cells (MSCs). The efficacy of using MSCs in treatment of OA was found to have a significant impact on the treatment and was focused on improving physical function and psychometric measures of pain. Although various available data and research studies regarding MSCs have shown their potential in clinical use, there is still limited data of MSCs regarding actual long-term safety and efficacy in larger clinical trials. To address these issues and inform future studies, we performed a clinical systematic review of MSC therapy for knee osteoarthritis combined with arthroscopy procedure. Cochrane (2022), EMBASE (2022), MEDLINE (2022) and PubMed (2022) were utilized as research platforms. Using the inclusion criteria, the total viable studies that were used within the systematic review amounts to around 18 studies. Clinically, MSCs treatment on OA have also reported improvements on the target site, such as that of articular cartilage, subchondral bone, and joint-space width. The results were obtained from data results of WOMAC, VAS, KOOS and ICRS, as well as through radiological imaging using MRI. However, there are still limitations that the reviews provide such as heterogeneity complications of MSCs of the studies reviewed, as well as the potential of risk bias assessment during publication. Therefore, future studies will need to address the evaluation of MSCs effect on cartilage regeneration on knee osteoarthritis (OA), improving structural outcomes of the knee, as well as its efficacy during combined treatment methods of arthroscopy.

12 June 2026 in Cell Transplantation
Verified
Journal Article
Open access
CSCynthia Retna Sartika
Cynthia Retna Sartika
RHRima Haifa
Rima Haifa
ACAngliana Chouw
Angliana Chouw
AHAtikah Anwar Hasibuan
Atikah Anwar Hasibuan
Karina KalasubaKarina Kalasuba
Karina Kalasuba
LULestari Mahardika Urbaningrum
Lestari Mahardika Urbaningrum
Mesenchymal stromal cell (MSC)–based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015–2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity. Although MSC therapy was generally well tolerated across studies, substantial outcome variability underscores the need for harmonized frameworks for dose selection, route optimization, and manufacturing consistency. This review highlights critical gaps in dose–route optimization and supports the development of standardized clinical guidelines and advanced strategies, including MSC priming and engineering, to improve therapeutic predictability and translational success.

13 March 2026 in Orthopedic Reviews
Verified
Journal Article
Open access
PDF file
YAYanuarso
Yanuarso
DDDitta Kalyani Devi
Ditta Kalyani Devi
KLKeri Lestari
Keri Lestari
CSCynthia Retna Sartika
Cynthia Retna Sartika
Karina KalasubaKarina Kalasuba
Karina Kalasuba
LULestari Mahardika Urbaningrum
Lestari Mahardika Urbaningrum
Background: Osteoarthritis (OA) is a degenerative joint disorder that causes pain, stiffness, and functional impairment. Conventional treatments relieve symptoms but do not restore cartilage, limiting long-term efficacy. Cell-based therapies, including mesenchymal stem cells (MSCs) and MSC-derived secretome, have emerged as promising strategies for cartilage regeneration. Object: This study aimed to assess the therapeutic effects of UC-MSCs and UC-MSC-derived secretome in OA patients through both clinical outcomes and synovial fluid (SF) analyses. Methods: Eligible participants were divided into two groups; group who underwent arthroscopy and group who did not. All the participants received an intra-articular injection consisting of an initial 2 mL dose of UC-MSC secretome, followed by 10 million UC-MSCs, and two additional 2 mL doses of secretome administered biweekly. Synovial fluid samples were collected at baseline and 12 weeks post-treatment, centrifuged to obtain the supernatant, and analyzed for inflammatory cytokines and matrix-degrading markers using multiplex and ELISA assays. Clinical evaluations were conducted at 6- and 12-months post-treatment. Result: The results showed that UC-MSC therapy significantly improved functional outcomes in patients with knee osteoarthritis, as indicated by WOMAC scores up to six months. In vitro studies showed similar results, where co-culture of osteoarthritic synovial fluid-derived MSCs with UC-MSCs or UC-MSC secretome enhanced proliferation and differentiation while rapidly reducing pro-inflammatory cytokines (IL-1β, IFN-γ, IL-6, IL-12p70, IL-17A, IL-18) and MMPs (MMP1, MMP7, MMP13). Conclusion: Our findings support a two-stage therapeutic strategy in which UC-MSC secretome first alleviates inflammation, followed by UC-MSCs to promote cartilage regeneration. Post-injection rehabilitation or repeated MSC dosing may further enhance treatment efficacy, highlighting the potential of MSC-based therapies for knee OA management.

1 January 2026 in Obstetrics and Gynecology International
Verified
Journal Article
Open access
BHBinarwan Halim
Binarwan Halim
CSCynthia Retna Sartika
Cynthia Retna Sartika
LSLaura Agnes Edessa Sibuea
Laura Agnes Edessa Sibuea
CWCarine Annabella Widjaja
Carine Annabella Widjaja
DNDiana Novia
Diana Novia
Karina KalasubaKarina Kalasuba
Karina Kalasuba
Background: Suboptimal sperm quality often poses a challenge to successful fertilization. This study hypothesizes that secretome could enhance sperm quality and increase the likelihood of successful pregnancy. This research aims to assess the impact of secretome on various sperm quality parameters, including concentration, motility, and DNA fragmentation, while considering patient‐related factors such as age, duration of abstinence, and body mass index (BMI). Method: An analysis involving 45 patients enrolled in the pregnancy program at Halim Fertility Center, Stella Maris Women’s and Children’s Hospital, Indonesia, from April to September 2023 was conducted. Semen samples from these patients were subjected to the swim‐up method and divided into two groups: Group A, which underwent swim‐up without secretome, and Group B, which underwent swim‐up with the addition of secretome. DNA fragmentation analysis was performed on the sperm swim‐up results from both groups. The sperm analysis data obtained before swim‐up (pretreatment) with those of Group A and Group B were compared. Result: The demographic data revealed an average age of 37.67 ± 5.36 years, abstinence duration of 4.00 ± 1.15 days, and BMI of 28.20 ± 3.49 kg/m 2 among the patients. No significant difference was observed in sperm concentration between pretreatment, Group A, and Group B (mil/mL) (36.2 ± 18.5; 36.3 ± 18.4; 36.6 ± 19.3). However, a significant difference was found in the rapid progressive motility of sperm across pretreatment, Group A, and Group B (%) (0.48 ± 1.32; 13.7 ± 8.3; 17 ± 8.3), as well as a significant reduction in DNA fragmentation in Group B compared to Group A (%) (3.48 vs. 4.39). Conclusions: The findings suggest that secretome enhances rapid progressive motility and reduces DNA fragmentation rates without affecting sperm concentration.